Skip to main content
Symptom
dx.
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Symptom
dx.
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Get Started
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Loading...
Spinal Cord Compression (Malignant)
Cardiovascular Presentations
Abdominal aortic aneurysm
Acute coronary syndrome (NSTEMI)
Acute coronary syndrome (STEMI)
Acute decompensated heart failure
Acute limb ischemia
Acute mesenteric ischemia
Aortic dissection
Aortic stenosis
Atrial fibrillation and flutter
Bradyarrhythmia and heart block
Cardiac arrest
Deep vein thrombosis
Myocarditis
Pericarditis
Pulmonary embolism
Stable angina
Superficial thrombophlebitis
Superior vena cava syndrome
Supraventricular tachycardia
Syncope (cardiogenic)
Unstable angina
Ventricular tachycardia
Respiratory Presentations
Acute bronchitis
Acute respiratory failure
Aspiration pneumonia
Asthma exacerbation
Bronchiolitis
Community-acquired pneumonia
COVID-19 pneumonia
COPD exacerbation
Croup
Croup (laryngotracheobronchitis)
Epiglottitis
Hemothorax
Hospital-acquired pneumonia
Pleural effusion
Pneumothorax (traumatic)
Pulmonary contusion
Spontaneous pneumothorax
Neurological Presentations
Bell's palsy
Benign paroxysmal positional vertigo
Brain abscess
Cauda equina syndrome
Cervical radiculopathy
Concussion (mild traumatic brain injury)
Encephalitis
Guillain-Barré syndrome
Hemorrhagic stroke (intracerebral)
Ischemic stroke
Lumbar radiculopathy
Malignant spinal cord compression
Migraine
Peripheral neuropathy (acute)
Retropharyngeal abscess
Schizophrenia (acute exacerbation)
Seizure (breakthrough:known epilepsy)
Seizure (first-time)
Spinal cord injury
Status epilepticus
Subarachnoid hemorrhage
Tension headache
Transient ischemic attack
Traumatic brain injury (moderate-severe)
Vestibular neuritis
Viral meningitis
Gastrointestinal Presentations
Acute appendicitis
Acute cholecystitis
Acute diverticulitis
Acute pancreatitis
Anal fissure
Choledocholithiasis and cholangitis
Clostridioides difficile colitis
Gastritis
Gastroenteritis (viral and bacterial)
Gastroesophageal reflux disease
Incarcerated or strangulated hernia
Inflammatory bowel disease flare
Large bowel obstruction
Lower GI hemorrhage
Peptic ulcer disease
Perforated viscus
Small bowel obstruction
Upper GI hemorrhage
Genitourinary and Reproductive Presentations
Acute prostatitis
Acute urinary retention
Ectopic pregnancy
Epididymitis
Orchitis
Ovarian torsion
Paraphimosis
Pelvic inflammatory disease
Priapism
Pyelonephritis
Renal laceration
Ruptured ovarian cyst
Testicular torsion
Tubo-ovarian abscess
Urinary tract infection (uncomplicated)
Urolithiasis (renal colic)
Vaginal bleeding (non-pregnant)
Infectious Disease Presentations
Acute sinusitis
Acute tonsillitis
Acute upper respiratory infection
Animal bite
Bacterial meningitis
Cellulitis
Conjunctivitis (bacterial)
Dental abscess
Endocarditis
Febrile neutropenia
Fournier gangrene
Hand-foot-mouth disease
Hepatitis (acute)
Herpes zoster
HIV-related illness
Human bite
Impetigo
Infected diabetic foot ulcer
Infectious mononucleosis
Influenza
Necrotizing fasciitis
Osteomyelitis
Otitis externa
Parasitic infection
Periorbital cellulitis
Peritonsillar abscess
Scabies
Sepsis
Septic arthritis
Spontaneous bacterial peritonitis
Tick-borne illness (Lyme disease)
Tinea infection
Tuberculosis
Viral exanthem
Wound infection
Trauma Presentations
Achilles tendon rupture
ACL and mceniscus tear
Ankle fracture
Ankle sprain
Burn
Calcaneus fracture
Cervical spine fracture
Clavicle fracture
Dental avulsion
Distal radius fracture
Drowning
Elbow fracture and dislocation
Electrical injury
Facial bone fracture
Facial laceration
Femur fracture
Fingertip amputation
Forearm fracture (radius and ulna)
Frostbite
Hand:finger laceration
Heat exhaustion
Heat stroke
Hip fracture
Humeral shaft fracture
Knee dislocation
Knee sprain
Lightning injury
Mandible fracture
Metacarpal fracture
Metatarsal fracture
Muscle strain
Nasal fracture
Non-accidental trauma
Orbital fracture
Patella fracture
Phalanx fracture (finger)
Proximal humerus fracture
Pulmonary contusion
Rib fracture
Rotator cuff tear (acute traumatic)
Scalp laceration
Scaphoid fracture
Shoulder dislocation
Skull fracture
Splenic laceration
Sternal fracture
Supracondylar pediatric fracture
Tendon laceration (hand:wrist)
Thoracic and lumbar spine fracture
Tibia:fibula fracture
Tibial plateau fracture
Toe fracture
Traumatic epistaxis
Traumatic hyphema
Toxicologic Presentations
Acetaminophen toxicity
Alcohol intoxication
Alcohol withdrawal
Anticholinergic toxicity
Anticoagulant overdose
Benzodiazepine overdose
Benzodiazepine:sedative overdose
Beta-blocker and calcium channel blocker toxicity
Carbon monoxide poisoning
Caustic ingestion
Digoxin toxicity
Drug eruption
Foreign body ingestion
Opioid intoxication
Opioid overdose
Opioid withdrawal
Organophosphate
Salicylate toxicity
Serotonin syndrome
Stimulant intoxication (cocaine, methamphetamine)
Tricyclic antidepressant overdose
Psychiatric Presentations
Acute anxiety
Acute psychosis
Agitation:behavioral emergency
Bipolar disorder
Conversion disorder
Major depressive episode
Neuroleptic malignant syndrome
Suicidal ideation and attempt
Musculoskeletal and Rheumatologic Presentations
Acute low back pain (mechanical)
Bursitis
Cervical radiculopathy
Costochondritis
Gout (acute)
Lumbar radiculopathy
Pseudogout
Tendinitis
Dermatology Presentations
Acute eczema (Eczema acute flare)
Allergic contact dermatitis
Erythema multiforme
Henoch-Schönlein purpura
Pressure injury
Psoriasis (acute flare)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Urticaria (acute)
Environmental and Exposure Presentations
Envenomation (snake, spider, insect)
High-altitude illness
Hypothermia
Hematologic and Oncologic Presentations
Acute chest syndrome
Coagulopathy
Hyperviscosity syndrome
Sickle cell crisis (vaso-occlusive)
Symptomatic anemia
Thrombocytopenia (severe)
Tumor lysis syndrome
Pediatric-Specific Presentations
Bronchiolitis
Croup
Emergency delivery
Febrile seizure
Kawasaki disease
Neonatal jaundice
Neonatal sepsis
Nursemaid's elbow
Pediatric fever 0 to 28 days
Pediatric fever 29 to 60 days
Pediatric fever 61 to 90 days
Pyloric stenosis
Slipped capital femoral epiphysis
Intussusception
Endocrine and Metabolic Presentations
Adrenal crisis
Diabetic ketoacidosis
Hypercalcemia
Hyperosmolar hyperglycemic state
Hypertensive emergency
Hypertensive urgency
Hypoglycemia
Myasthenia gravis crisis
Myxedema coma
Severe hyperkalemia
Severe hyponatremia
Thyroid storm
ENT and Maxillofacial Presentations
Acute laryngitis
Acute otitis media
Acute pharyngitis
Cerumen impaction
Epistaxis (anterior)
Nasal foreign body
Otitis externa
Tympanic membrane perforation
Ophthalmologic Presentations
Acute angle-closure glaucoma
Central retinal artery occlusion
Chemical eye injury
Corneal abrasion
Corneal ulcer
Globe rupture
Ocular foreign body
Orbital cellulitis
Retinal detachment
Obstetric Presentations
Hyperemesis gravidarum
Painful vaginal bleeding in pregnancy
Placenta previa
Placental abruption
Preeclampsia:eclampsia
Preterm labor
Threatened:inevitable:incomplete abortion
Systemic and Miscellaneous Presentations
Anaphylaxis
Angioedema
Cannabis-induced hyperemesis
Spinal Cord Compression (Malignant)
POCUS
Procedures
Calculators
Resuscitation
ECG Guide
Back
Clinical Assessment Checklist
Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Oncologic emergency recognition
▶
MSCC is a time-sensitive neurologic emergency requiring immediate action
▶
Neurologic outcome is directly linked to ambulatory status at presentation
Paraplegic >24 hours before treatment — surgical benefit diminishes significantly
Activate oncology/neurosurgery/radiation oncology pathway immediately
▶
Notify spine surgery for emergent surgical evaluation
Neurosurgery or orthopedic spine on-call paged within 30 minutes of diagnosis
Initiate dexamethasone without waiting for MRI confirmation if high clinical suspicion
▶
Class I recommendation based on NCCN guidelines
Dexamethasone 10–16 mg IV bolus immediately upon clinical suspicion
Neurological stabilization
Airway threat from high cervical lesions
▶
Diaphragmatic compromise with C3–C5 lesions
▶
Respiratory failure may develop acutely
Anesthesia and critical care involvement for airway planning
SpO2 target 94–98%
▶
Supplemental O2 titrated to target
If unable to protect airway, rapid sequence intubation
Spinal shock from cervical or upper thoracic lesions
▶
Hypotension with paradoxical bradycardia
▶
SBP <90 mmHg with HR <60 — neurogenic shock pattern
Vasopressors: norepinephrine 0.01–0.5 mcg/kg/min, titrate to MAP >85 mmHg
Avoid hypotension — cord ischemia worsens with MAP <85 mmHg in acute SCI
▶
Target MAP 85–90 mmHg for first 7 days per spinal cord injury guidelines
Immobilization
▶
Spinal precautions until imaging confirms stability
▶
Log roll for repositioning
Spine board or rigid cervical collar if cervical lesion suspected
Key decision points
Neurologic status at presentation
▶
Ambulatory — highest priority for urgent but not emergent surgery/RT
▶
Outcomes: 75% remain ambulatory at 6 months
Non-ambulatory — most urgent; surgical decompression within 24 hours if candidate
▶
Every hour of additional deficit reduces recovery probability
Paraplegic >48 hours — surgical benefit markedly reduced; RT/medical management
Consult triggers
▶
Spine surgery — all patients with neurologic deficits or instability
Radiation oncology — all patients for RT planning
Medical oncology — systemic therapy planning and tumor histology guidance
Palliative care — goals of care for poor prognosis or non-surgical candidates
History
Presenting symptoms
Pain characteristics
▶
Back pain in 83–96% of patients; may precede neurologic deficits by weeks
▶
Local axial pain over affected vertebra — most common
Radicular pain in dermatomal band-like distribution
Referred pain patterns: cervical lesions to midscapular; thoracic to hip; lumbosacral to thoracic
Pain worse when supine with nocturnal awakening — distinguishing from degenerative disease
▶
Exacerbated by Valsalva, coughing, sneezing, or straining — suggests epidural involvement
Pain unrelenting, progressive, and unresponsive to analgesics — alarm feature
Neurologic symptoms
Motor deficits
▶
Progressive weakness in extremities
▶
Upper extremity weakness — cervical lesion
Lower extremity weakness — thoracic or lumbar lesion
Gait difficulty — early ambulatory compromise
Inability to ambulate — advanced motor deficit; strongest prognostic indicator
Sensory changes
▶
Numbness or paresthesias below a dermatomal level
Saddle anesthesia — cauda equina involvement
Autonomic dysfunction
▶
Urinary retention with overflow incontinence — pathognomonic for cauda equina
▶
90% sensitivity, 95% specificity for cauda equina syndrome
Constipation or bowel incontinence — neurogenic bowel
Autonomic dysreflexia in cervical or upper thoracic lesions
Cancer history
Known malignancy
▶
Tumor type and stage — prostate, breast, lung account for 15–20% each
▶
Lymphoma, renal cell carcinoma, myeloma each 5–10%
MSCC is first manifestation of cancer in approximately 20% of patients
Prior spinal radiation — limits retreatment options; must be documented
Prior spinal surgery — instrumentation affects surgical planning
Prior MSCC episodes — recurrence rate 7–14%
Systemic therapy history
▶
Current chemotherapy, targeted therapy, or immunotherapy
Response status — progressive vs. stable disease
Performance status: KPS or ECOG — critical for treatment decision-making
Tempo and timeline
Onset and progression rate
▶
Gradual over days to weeks — typical presentation
Acute collapse with sudden paraplegia — pathologic fracture pattern
Rate of onset is the strongest predictor of neurologic irreversibility
Functional baseline
▶
Ambulatory status before symptom onset
Activities of daily living capacity
Goals of care and advance directives — essential for treatment planning
Physical Exam
Vital signs
Hemodynamic assessment
▶
Hypotension with bradycardia — neurogenic shock from cervical or upper thoracic lesion
Tachycardia — may reflect autonomic dysfunction or PE (high VTE risk in MSCC)
Temperature — fever suggests concurrent infection or epidural abscess
Spine examination
Focal spinal tenderness
▶
Percussion tenderness over affected vertebra — sensitivity 66–90% for MSCC
Palpable step-off or vertebral deformity — pathologic fracture
Paraspinal muscle spasm
Range of motion limitation
▶
Cervical extension restriction
Lumbar flexion limitation with radiation into legs
Neurological examination
Motor assessment
▶
Systematic myotomal strength testing 0–5 scale all extremities
▶
Document motor level: most caudal level with normal strength bilaterally
Gait evaluation if ambulation possible
▶
Tandem gait — early myelopathy sign
Sensory assessment
▶
Sensory level to pinprick and light touch
▶
Maps to cord level: sensory level typically 1–2 segments below cord lesion
Proprioception and vibration — posterior column involvement
Saddle anesthesia to perianal pinprick — cauda equina
Reflexes
▶
Hyperreflexia and Babinski sign — upper motor neuron; lesion above conus
Hyporeflexia or areflexia — lower motor neuron; cauda equina syndrome
Clonus — sustained clonus indicates significant myelopathy
Rectal examination
▶
Anal sphincter tone — decreased in cauda equina syndrome
Perianal sensation to pinprick
Bladder assessment
Postvoid residual
▶
Bladder scan or catheterization for PVR measurement
▶
PVR >150 mL — significant retention; bladder catheterization indicated
Absence of PVR virtually excludes cauda equina syndrome — 99.99% NPV
Urinary retention on initial presentation — poor prognostic sign
Frankel grading
Ambulatory status documentation
▶
Frankel A — complete loss of motor and sensory function below lesion
Frankel B — sensory function only below lesion; no motor function
Frankel C — useless motor function below lesion
Frankel D — useful motor function below lesion; ambulatory with or without aids
Frankel E — normal motor and sensory function
Differential Diagnosis
Epidural causes
Malignant epidural spinal cord compression
▶
ICD-10: G99.2; C79.51 (secondary malignant neoplasm of vertebrae)
▶
Known malignancy; MRI shows epidural mass with cord compression
Most common at thoracic level (60%)
Epidural abscess
▶
ICD-10: G06.1
▶
Fever, elevated ESR/CRP, elevated WBC, recent procedure or immunosuppression
MRI with ring-enhancing epidural collection; gadolinium-enhancing rim
Vertebral causes
Pathologic vertebral compression fracture without cord compression
▶
ICD-10: M48.50
▶
Pain without neurologic deficit; MRI shows marrow replacement without epidural extension
Osteoporotic compression fracture
▶
ICD-10: M80.08XA
▶
Elderly patient; low bone density; no malignancy history; benign-appearing MRI signal
Intramedullary causes
Intramedullary spinal cord metastasis
▶
ICD-10: G99.2; C79.49
▶
Rare; central cord syndrome pattern; lung cancer most common primary
MRI shows intramedullary T2 signal change with enhancing lesion
Transverse myelitis
▶
ICD-10: G37.3
▶
Inflammatory; often post-infectious or autoimmune; no cancer history
MRI shows central cord T2 hyperintensity; CSF pleocytosis
Leptomeningeal causes
Leptomeningeal carcinomatosis
▶
ICD-10: C79.32
▶
Multifocal cranial neuropathies, radiculopathies; CSF cytology positive
MRI leptomeningeal enhancement; diffuse vs. focal epidural mass
Radiation myelopathy
▶
ICD-10: G95.89
▶
History of prior spinal RT; delayed onset months to years; progressive course
MRI shows T2 signal change in radiation field
Functional mimics
Conus medullaris syndrome
▶
Lesion at T12–L1; mixed UMN and LMN findings; early bowel/bladder involvement
Cauda equina syndrome (non-malignant)
▶
ICD-10: G83.4
▶
Disc herniation, hematoma, or abscess; similar presentation to MSCC at lumbar level
Paraneoplastic myelopathy
▶
ICD-10: G13.0
▶
Subacute onset; associated antibodies (anti-amphiphysin, anti-CRMP5)
Laboratory Tests
Hematologic studies
Complete blood count
▶
Anemia of chronic disease — common with advanced malignancy
▶
Hb <80 g/L may affect surgical candidacy
Leukocytosis — infection vs. steroid effect; differentiate from epidural abscess
Thrombocytopenia — affects surgical and anticoagulation planning
Metabolic studies
Comprehensive metabolic panel
▶
Creatinine and eGFR — MRI with gadolinium; contrast planning; NSF risk
▶
Gadolinium contraindicated if eGFR <30 mL/min/1.73m2
Calcium — hypercalcemia of malignancy in 10–20% of cases
▶
Corrected calcium >2.75 mmol/L — treat hypercalcemia concurrently
Glucose — steroid-induced hyperglycemia common with dexamethasone
▶
Monitor glucose every 4–6 hours after dexamethasone initiation
LFTs — liver metastases; drug metabolism for opioids and steroids
Coagulation studies
Preoperative coagulation
▶
PT/INR — anticoagulant status; INR >1.5 increases surgical bleeding risk
PTT — heparin effect
Platelet count — surgical threshold typically >80 x 10^9/L
Type and screen
▶
Vascular tumors (renal cell carcinoma, thyroid) can bleed significantly at surgery
▶
Cross-match 2–4 units pRBC if renal cell or thyroid primary
Tumor markers and special studies
Tumor-specific markers
▶
PSA — prostate cancer (most common male primary)
SPEP/UPEP with free light chains — multiple myeloma
LDH — lymphoma (elevated LDH suggests high-grade disease)
CEA, CA19-9 — colorectal, pancreatic primaries if unknown primary
Inflammatory markers
▶
ESR and CRP — elevated in both malignancy and epidural abscess; use for differentiation
▶
Very high CRP (>150 mg/L) with fever favors abscess over tumor
Urinalysis
▶
UA for urinary retention with suspected UTI from indwelling catheter
Urine culture if symptomatic or catheterized
Diagnostic Tests
Scoring Systems
Frankel grading scale
▶
Standard functional classification for MSCC severity
▶
Frankel A: complete motor and sensory loss below lesion
Frankel B: sensory preservation only
Frankel C: non-functional motor preservation
Frankel D: functional motor preservation; ambulatory
Frankel E: neurologically intact
SINS (Spinal Instability Neoplastic Score)
▶
18-point score guiding surgical stabilization decisions
▶
Location: 0–3 points (junctional spine highest risk)
Pain relief with recumbency: 0–3 points
Lesion type: 0–2 points (lytic worst, blastic best)
Radiographic spinal alignment: 0–4 points
Vertebral body involvement: 0–3 points
Posterior element involvement: 0–3 points
SINS 0–6: stable — no surgery required for instability
SINS 7–12: potentially unstable — surgical consultation recommended
SINS 13–18: unstable — surgical stabilization indicated
Tokuhashi score
▶
15-point prognostic score predicting survival
▶
General condition (KPS): 0–2 points
Number of extraspinal bone metastases: 0–2 points
Number of vertebral metastases: 0–2 points
Number of internal organ metastases: 0–2 points
Primary cancer type: 0–5 points
Palsy: 0–2 points
Score 0–8: predicted survival <6 months — palliative treatment
Score 9–11: predicted survival 6–12 months — palliative or excisional surgery
Score 12–15: predicted survival >12 months — excisional surgery may be considered
NOMS framework (Neurologic, Oncologic, Mechanical, Systemic)
▶
Structured decision framework integrating tumor biology and mechanical stability
▶
Neurologic: degree and rate of deficit
Oncologic: tumor radiosensitivity (radiosensitive vs. radioresistant)
Mechanical: SINS score for stability
Systemic: overall cancer burden and treatment tolerance
MRI
MRI entire spine with and without gadolinium
▶
Gold standard for MSCC diagnosis
▶
Sensitivity 44–93%, specificity 90–98% for epidural cord compression
NCCN recommends entire spine imaging regardless of clinical level
Must image entire spine — 15–20% have additional lesions at other levels
▶
Up to one-third of patients have multiple noncontiguous levels of involvement
Urgency: obtain within 24 hours of symptom onset; emergent if acute deficit
MRI sequences and interpretation
▶
T1 — vertebral body marrow signal: hypointense in tumor infiltration
▶
Loss of normal fatty marrow signal
T2 — cord signal: hyperintensity indicates edema or myelomalacia
▶
T2 cord signal change correlates with severity and prognosis
STIR — highly sensitive for marrow edema and tumor infiltration
▶
Useful when gadolinium is contraindicated
Post-gadolinium T1 — differentiates tumor from abscess (ring enhancement vs. homogeneous)
▶
Leptomeningeal disease: linear enhancement over cord surface
Epidural Spinal Cord Compression Scale (ESCC)
▶
Six-point grading of epidural disease on axial MRI
▶
Grade 0: bone only, no epidural disease
Grade 1a: epidural impingement without thecal sac deformation
Grade 1b: thecal sac deformation without cord contact
Grade 1c: cord contact without cord compression
Grade 2: cord compression with CSF visible around cord
Grade 3: cord compression, no CSF visible; ESCC 3 = highest risk
CT
CT spine
▶
Indications and role
▶
MRI contraindicated (pacemaker, ferromagnetic implants) — CT myelogram alternative
Superior bone detail: pathologic fracture assessment, cortical destruction
Surgical planning: pedicle screw placement, vertebral body integrity
CT chest/abdomen/pelvis
▶
Staging and unknown primary workup
Lung cancer — most common unknown primary to present with MSCC
CT myelogram
▶
Sensitivity and specificity equivalent to MRI when MRI contraindicated
Intrathecal contrast injection; invasive; risk of post-procedure headache
Bone windows interpretation
▶
Lytic lesion — bone destruction; renal, thyroid, lung, breast cancer
▶
Greatest instability risk with >50% vertebral body involvement
Blastic lesion — bone formation; prostate cancer, carcinoid
▶
More mechanically stable than lytic lesions
Mixed pattern — lung, breast cancer
Ultrasound
Ultrasound in MSCC evaluation
▶
Limited direct role for spinal cord assessment
▶
Spinal cord not accessible to ultrasound in adults beyond neonatal period
Bladder ultrasound — essential
▶
Postvoid residual measurement to assess for neurogenic bladder
PVR >150 mL indicates retention requiring catheterization
Intraoperative ultrasound
▶
Used during laminectomy to confirm adequacy of cord decompression
Real-time guidance for tumor resection margins
FAST and point-of-care ultrasound
▶
Not a primary diagnostic modality for MSCC
▶
Useful to evaluate hemodynamically unstable patients for concurrent pathology
DVT assessment in lower extremities — high VTE risk in immobilized MSCC patients
Disposition
Admission criteria
All patients with confirmed or suspected MSCC
▶
Mandatory inpatient admission for all symptomatic patients
▶
New or progressive neurologic deficit — emergent admission
Intractable pain — urgent admission
ICU or high-dependency unit for
▶
Cervical lesions with respiratory compromise
Neurogenic shock requiring vasopressors
Rapidly deteriorating neurologic status
Surgical candidacy evaluation
Factors favoring surgical decompression
▶
Good performance status (KPS >70, ECOG 0–2)
▶
Expected survival >3–6 months
SINS score 7–18 (unstable or potentially unstable)
Radioresistant tumor histology (renal cell, sarcoma, melanoma, thyroid)
Neurologic deficit from single-level compression
Prior radiation to same site (reirradiation not feasible)
Factors against surgery
▶
Poor performance status (KPS <40)
Complete paraplegia >48 hours
Multiple levels of compression with widespread systemic disease
Patient preference for non-operative management
Transfer criteria
Transfer to spine surgery center
▶
Surgical candidate but no spine surgery capability at presenting facility
▶
Transfer within 24 hours for non-ambulatory patients
Emergent transfer for deteriorating ambulatory patients
Dexamethasone loading dose given before transfer
Airway management and monitoring during transport for cervical lesions
Discharge criteria
Copy
Not appropriate for discharge from ED
▶
Any neurologic deficit attributable to MSCC requires admission
Incidental asymptomatic vertebral metastases without compression — outpatient referral acceptable with urgent (<48 hour) spine/oncology follow-up
Treatment
Corticosteroids
Dexamethasone — initiate immediately upon clinical suspicion
▶
NCCN recommended standard dose: 4 mg IV every 6 hours (16 mg/day total)
▶
Initiate before MRI confirmation if high clinical suspicion
NCCN CNS Cancers Guidelines v1.2026
High-dose protocol: 96 mg IV bolus
▶
Supported by randomized trial for improved ambulatory outcomes
Higher adverse effect rate: 14% serious AEs vs. 0% with standard dosing
Cochrane 2015 Systematic Review — no clear superiority for neurologic recovery
Taper strategy
▶
Begin taper over 1–2 weeks once definitive treatment (RT or surgery) initiated
If no radiotherapy planned, longer taper guided by symptom response
Concurrent protective medications
▶
PPI or H2 blocker — GI prophylaxis, especially perioperative or with NSAIDs
PJP prophylaxis if steroids anticipated >4 weeks at dexamethasone >3 mg/day equivalent
Blood glucose monitoring every 4–6 hours; insulin sliding scale as needed
Radiation therapy
Conventional external beam radiation therapy (cEBRT)
▶
Indications
▶
Radiosensitive tumors (lymphoma, myeloma, prostate, breast)
Non-surgical candidates or patient declines surgery
Post-surgical adjuvant RT to residual or adjacent disease
Typical regimens
▶
30 Gy in 10 fractions — most common palliative regimen
20 Gy in 5 fractions — shorter course for poor performance status
8 Gy in 1 fraction — single fraction for very short prognosis
ASTRO Bone Metastasis Guidelines 2024
Initiation timing
▶
Begin within 24 hours of diagnosis in non-surgical candidates with deficit
Stereotactic body radiotherapy (SBRT)
▶
Indications
▶
Radioresistant tumors (renal cell, sarcoma, melanoma, thyroid)
Reirradiation of previously treated sites
Post-operative consolidation after separation surgery
Dose fractionation
▶
18–24 Gy in 1 fraction for radioresistant histologies
24–27 Gy in 3 fractions for post-operative treatment
ESCC score <2 required before SBRT to avoid radiation myelopathy
Requires surgical separation if ESCC grade 2–3 before SBRT delivery
Surgery
Separation surgery with adjuvant SBRT
▶
Current standard of care for surgical candidates with MSCC
▶
Goals: decompress cord, stabilize spine, create 2–3 mm separation from cord for SBRT
Not aimed at complete tumor removal — reduces morbidity
Preferred approach: posterior decompression with instrumented fusion
▶
Posterolateral decompression with pedicle screw fixation
Anterior approach for anterior column disease with good prognosis and kyphosis
Patchell RCT (2005) — landmark trial showing surgery + RT superior to RT alone
▶
84% vs. 57% maintained or regained ability to walk
122 days vs. 13 days median ambulatory duration
Lancet Oncol 2005
Percutaneous vertebroplasty and kyphoplasty
▶
Indications: pain control for vertebral compression fractures without significant cord compression
▶
Not for patients with posterior cortex destruction or epidural tumor
Cement augmentation stabilizes pathologic fracture
▶
Pain relief in 70–90% within 48 hours
Minimally invasive spine stabilization
▶
MIS techniques reduce blood loss and complication rates vs. open surgery
▶
Particularly beneficial for multilevel disease and high surgical risk patients
Analgesics and symptom management
Pain management
▶
Opioid analgesics — first-line for moderate to severe pain
▶
Morphine oral: 5–10 mg every 4 hours (opioid-naive)
IV morphine: 2–4 mg every 3–4 hours titrate to comfort
Patient-controlled analgesia for severe intractable pain
NSAIDs — adjunct with caution; avoid with concurrent steroids (GI risk)
Gabapentin — neuropathic pain adjunct
▶
100–300 mg orally three times daily; titrate to 900–1800 mg/day
Bowel and bladder management
▶
Urinary catheterization for retention — Foley catheter
Stool softeners: docusate sodium 100–200 mg twice daily
Stimulant laxatives for opioid-induced constipation: senna 8.6 mg twice daily
VTE prophylaxis
Anticoagulation — mandatory for immobilized MSCC patients
▶
High VTE risk: spinal cord injury + immobility + malignancy
▶
10–50% incidence of DVT in untreated SCI patients
Pharmacologic prophylaxis
▶
Low molecular weight heparin: enoxaparin 40 mg SC daily (CrCl >30 mL/min)
Unfractionated heparin 5000 units SC every 8 hours if CrCl <30 mL/min
Initiate 24–48 hours post-surgery once surgical bleeding risk acceptable
Mechanical prophylaxis
▶
Sequential compression devices — initiate immediately on admission
Continue mechanical until pharmacologic VTE prophylaxis initiated
Special Populations
Pregnancy
MSCC in pregnancy — rare but oncologic emergency
▶
MRI without gadolinium preferred
▶
Gadolinium crosses placenta — avoid in first trimester; use only if essential
Non-gadolinium MRI maintains high sensitivity for cord compression
Dexamethasone
▶
Generally safe across all trimesters at standard doses
Increased risk of gestational diabetes with steroid use — monitor glucose
Betamethasone may be preferred for fetal lung maturity if preterm delivery anticipated
Radiation therapy considerations
▶
Fetal shielding essential; quantify fetal dose before RT
SBRT with fetal shielding may be feasible for lumbar/lumbosacral lesions
Thoracic RT carries lower fetal exposure risk than lumbar
Surgical decompression
▶
Feasible in all trimesters if maternal neurologic status mandates
Fetal monitoring throughout procedure
Obstetrics and maternal-fetal medicine co-management required
Geriatric
Frailty and performance status
▶
Standard performance status tools may underestimate frailty
▶
Comprehensive geriatric assessment before major surgical intervention
Karnofsky Performance Status <50 — high surgical risk; favor RT
Comorbidity burden affects treatment tolerance
▶
Cardiac and pulmonary disease — increased perioperative risk
Renal impairment — affects contrast use and LMWH dosing
Dexamethasone considerations in elderly
▶
Higher risk of steroid-induced hyperglycemia in diabetics and pre-diabetics
▶
More frequent glucose monitoring; earlier insulin initiation
Increased delirium risk — avoid benzodiazepines; minimize sedating medications
Steroid-induced myopathy may compound immobility from cord compression
Single-fraction RT
▶
8 Gy in 1 fraction increasingly appropriate for frail elderly with short prognosis
▶
Minimizes treatment burden and hospital trips
Palliative goals of care conversation — essential before invasive intervention
Fall risk
▶
Gait instability from cord compression + age-related balance deficits — highest fall risk
▶
PT and OT evaluation for mobility aids and home safety planning
Pediatrics
MSCC in children — rare; different primary tumor spectrum
▶
Common pediatric primaries
▶
Neuroblastoma — most common solid tumor with spinal involvement in children
Ewing sarcoma, osteosarcoma, rhabdomyosarcoma
Leukemia/lymphoma — may present with epidural disease
MRI imaging
▶
Sedation or anesthesia may be required for young children
MRI without gadolinium preferred if diagnosis established
Dexamethasone dosing in children
▶
1 mg/kg/day IV divided every 6 hours (max 16 mg/day)
Or 0.5 mg/kg/dose IV every 6 hours
Radiation considerations in children
▶
Growth plate damage and spinal deformity risk from RT
▶
Vertebral body irradiation may cause scoliosis — weigh against neurologic benefit
Proton beam therapy preferred when available — reduced scatter dose to growing spine
SBRT increasingly used in adolescents to minimize dose to normal tissues
Surgical considerations
▶
Weight-based dosing for anesthesia
Pediatric neurosurgery consultation required — adult techniques not directly transferable
Posterior decompression techniques adapted for smaller anatomy
Background
Epidemiology
Incidence and prevalence
▶
MSCC affects approximately 2–5% of all cancer patients
▶
Estimated 20,000–25,000 cases per year in the United States
Thoracic spine involved in 60% of cases
▶
Lumbar spine 25%
Cervical spine 15%
Multiple noncontiguous levels in up to one-third of patients
Primary tumor distribution
▶
Prostate cancer: 15–20% of MSCC cases
Breast cancer: 15–20%
Lung cancer: 15–20%
Lymphoma: 5–10%
Renal cell carcinoma: 5–10%
Multiple myeloma: 5–10%
Unknown primary in approximately 7% of MSCC presentations
Prognosis
▶
Median survival overall: 3–6 months
▶
Longer with favorable histology (breast, prostate, lymphoma, myeloma)
Shorter with lung, renal, or colorectal primary
Ambulatory patients at treatment: 75% remain ambulatory at 6 months
Non-ambulatory patients at treatment: 10–30% recover ambulation
Pathophysiology
Mechanisms of spinal cord compression
▶
Hematogenous spread to vertebral body — most common route
▶
Batson venous plexus: valveless epidural venous system allows retrograde tumor spread
Preferential thoracic involvement due to vertebral volume and rich blood supply
Direct tumor extension from paravertebral lymph nodes
▶
Intervertebral foramina entry — lymphoma and lung cancer common
Leptomeningeal carcinomatosis — diffuse tumor in subarachnoid space
Pathophysiology of cord injury
▶
Mechanical compression causing direct ischemia of cord parenchyma
▶
Epidural venous plexus congestion exacerbates ischemia
Inflammatory cascade — VEGF release, edema formation
▶
Dexamethasone works primarily by reducing vasogenic edema
Progressive cord ischemia leads to irreversible myelomalacia if untreated
▶
Time-dependent: neurologic injury accelerates as compression worsens
Vertebral instability mechanisms
▶
Lytic destruction of >50% vertebral body — pathologic fracture risk
Pedicle erosion — loss of posterior column integrity
Junctional spine (cervicothoracic, thoracolumbar, lumbosacral) — highest instability risk
Therapeutic Considerations
Treatment decision framework
▶
NOMS framework guides individualized management
▶
Neurologic deficit severity and progression rate
Oncologic: tumor radiosensitivity stratification
Mechanical: SINS instability scoring
Systemic: overall tumor burden and treatment tolerance
Radiosensitive tumors — cEBRT alone or after decompressive surgery
▶
Lymphoma, myeloma, small cell lung, prostate, breast, seminoma
Radioresistant tumors — SBRT required with or without surgery first
▶
Renal cell carcinoma, sarcoma, melanoma, thyroid, non-small cell lung
Surgery vs. radiation evidence base
▶
Patchell RCT (2005) — decompressive surgery + RT vs. RT alone
▶
84% vs. 57% ability to walk post-treatment
Surgery group walked longer (median 122 vs. 13 days)
NNT 3.7 patients treated to preserve one patient's ambulation
Cochrane 2015 — no high-quality evidence favoring high-dose over standard-dose dexamethasone
▶
High-dose carries significantly higher adverse effect rate
Emerging therapies
▶
Targeted therapy and immunotherapy reducing need for emergent intervention in some histologies
▶
BRAF inhibitors for melanoma; EGFR/ALK inhibitors for lung; anti-androgens for prostate
Pre-emptive screening MRI for high-risk patients (PROMPTS trial, Lancet Oncol 2022)
▶
Screening castration-resistant prostate cancer patients with vertebral mets for early MSCC detection
Patient Discharge Instructions
copy discharge instructions
Copy
Spinal cord compression from cancer — what to know
▶
Your cancer has caused pressure on your spinal cord or the nerves near your spine
▶
You were treated with steroids (dexamethasone) to reduce swelling
You may be scheduled for radiation therapy, surgery, or both
Take all prescribed medications as directed
▶
Dexamethasone — do not stop suddenly; taper only as directed by your doctor
Stomach protection medication (antacid) — take with steroids to protect your stomach
Pain medications — take as prescribed; do not drive while using opioids
Monitor your blood sugar if you are diabetic or are prescribed steroids
▶
Steroids can raise your blood sugar significantly
Activity restrictions
▶
Follow all mobility restrictions given by your care team
▶
Do not lift heavy objects unless cleared by spine surgery
Use all mobility aids (walker, brace) as prescribed
Prevent falls
▶
Your balance and leg strength may be affected
Bathroom safety: grab bars, non-slip mats
Ask for help getting up from bed or chairs
Bowel and bladder care
▶
If you have a urinary catheter, keep the catheter clean and the bag below bladder level
High-fiber diet and stool softeners to prevent constipation
Report inability to urinate or bowel incontinence immediately
Return to emergency department immediately for
▶
New weakness or worsening weakness in your arms or legs
New or worsening numbness or tingling anywhere in the body
Loss of bladder or bowel control (new incontinence or inability to urinate)
Worsening or new back pain that is not relieved by your medications
Inability to walk or new significant gait difficulty
Falls
Difficulty breathing (especially if you have a neck or upper back lesion)
Fever over 38.5°C (101.3°F)
Follow-up care
▶
Radiation oncology appointment within 24–48 hours if radiation planned
Spine surgery follow-up within 1 week if surgical treatment performed
MRI spine follow-up at 1–3 months after treatment per your oncologist
Physiotherapy and occupational therapy referral for rehabilitation
References
Guidelines and key sources
NCCN Clinical Practice Guidelines in Oncology — Central Nervous System Cancers v1.2026
▶
National Comprehensive Cancer Network; updated April 23, 2026
▶
SPINE-1 algorithm: workup and management of metastatic spine tumors
Dexamethasone dosing, surgical, and RT recommendations
Patchell RA et al. — Lancet Oncology 2005
▶
Landmark RCT: direct decompressive surgery vs. radiation therapy for MSCC
▶
Surgery + RT superior: 84% vs. 57% ambulatory post-treatment
Foundation for surgical decompression recommendation
ASTRO Clinical Practice Guideline — Bone Metastases — Practical Radiation Oncology 2024
▶
External beam RT fractionation guidance including single fraction regimens
▶
Supports 8 Gy x1, 20 Gy x5, 30 Gy x10 as equivalent for pain palliation
Supporting studies
Ropper AE, Ropper AH — NEJM 2017
▶
Acute Spinal Cord Compression — comprehensive review
▶
Clinical assessment, MRI interpretation, management algorithm
Cole JS, Patchell RA — Lancet Neurology 2008
▶
Metastatic epidural spinal cord compression review
▶
Pathophysiology, clinical features, management principles
George R et al. — Cochrane Database of Systematic Reviews 2015
▶
Interventions for treatment of metastatic extradural MSCC
▶
No clear superiority of high-dose over standard-dose corticosteroids
High-dose steroids: 14% serious adverse events vs. 0%
Singer E et al. — Annals of Medicine 2025
▶
Initial management and disposition of MSCC in the ED
▶
Practical emergency medicine guidance for MSCC workup
Lawton AJ et al. — Journal of Clinical Oncology 2019
▶
Multidisciplinary review of MSCC assessment and management
▶
Risk stratification, treatment pathways, rehabilitation
Dearnaley D et al. — Lancet Oncology 2022 (PROMPTS trial)
▶
Screening MRI for MSCC in castration-resistant prostate cancer
▶
Pre-emptive treatment reduces neurologic deficit incidence
Spratt DE et al. — Lancet Oncology 2017
▶
International Spine Oncology Consortium — integrated multidisciplinary algorithm
▶
NOMS framework validation and surgical vs. RT decision guidance
Bassa BA et al. — Injury 2025
▶
VTE risk in acute spinal cord injury
▶
Supports mandatory VTE prophylaxis in MSCC patients
Prasad D, Schiff D — Lancet Oncology 2005
▶
Malignant spinal cord compression review
▶
Epidemiology, primary tumor distribution, prognostic factors
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.
← Management Protocols
Home
Management Protocols
Spinal Cord Compression (Malignant)